Biosensor bracelet to monitor immunotherapy response in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a wearable bracelet can help track how well immunotherapy is working for advanced lung cancer. It looks at daily activity and sleep patterns to find early clues about treatment response, which could help doctors personalize care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB or IV) non-small cell lung cancer (NSCLC).
- You are currently being treated with an immunotherapy drug called pembrolizumab, atezolizumab, or nivolumab (sometimes alongside chemotherapy).
- You are receiving care at Ysbyty Gwynedd hospital.
- You are generally well enough to take part (a performance status score of 0 or 1).
- You are able to wear a small sensor bracelet on your wrist.
- You do not have complete hair loss on your head.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial checks whether a device called TheraSure CNI-Monitor can be used while people with advanced lung cancer receive immunotherapy. It aims to improve monitoring during palliative (comfort-focused) treatment.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.